Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Evans John M.

Simon Amy

Ciaramella Giuseppe

Cathie Wood's Ark Invest has significantly increased its position in Beam Therapeutics, a biotech company using base editing technology for genetic treatments. With multiple clinical programs advancing toward FDA approval and sufficient cash runway through mid-2029, Beam could transform into a commercial biotech company. However, the investment remains speculative and dependent on successful clinical trials and regulatory approvals.

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?

Not financial advice. Focused on compelling growth opportunities for high-alpha market returns in multiple sectors.

J Keynes

CEO of The Tribeca Trade Group (TTG) Ex BAML Director ETF & D1 Trading. Momentum & Trend Trader. My MO: stay 1 step ahead of trends & momentum for TTG members

Christian Fromhertz ??

Trader & Student of the Market  • Co-Founder of @TraderLion+@Deepvue • The Trader's Handbook https://t.co/wwGdE6Xg79 • Sharing lessons from 100+ Market Wizards

Richard Moglen

??U.S. Army Veteran??

Build • Collaborate • Grow
featured in @Benzinga's Small Cap Conference #DayTrading

NOT INVESTMENT ADVICE! 

contains referral links

Andy (Mighty Soldiers Trades)

Trader, Author, Orophile, Technical Analysis Multiple Timeframes https://t.co/E4cQoecQva Only Price Pays®  Maximum Trading Gains w/⚓VWAP https://t.co/4RBYa3EFPj

Beam Therapeutics Inc (BEAM) Stock Price, Analysis & Trade Signals